Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935971 · ClinicalTrials.gov registry record · Phase 4
The Effects of Dupilumab on Allergic Contact Dermatitis
A Phase 4 study of Allergic Contact Dermatitis, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03935971 is a Phase 4 study of Allergic Contact Dermatitis that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants, below the 26-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03935971, a Phase 4 study of Allergic Contact Dermatitis, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital, Department of Dermatology - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935971
The ClinicalTrials.gov registry entry for NCT03935971 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26-participant average among 3 other Allergic Contact Dermatitis trials with a reported enrollment target (35% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Contact Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03935971 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03935971 about?
NCT03935971 is a clinical study titled "The Effects of Dupilumab on Allergic Contact Dermatitis". The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
What is the current status of trial NCT03935971?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2019-12-18. Estimated completion is 2026-07-31.
What conditions does trial NCT03935971 study?
This clinical trial studies the following conditions: Allergic Contact Dermatitis.
What interventions are being tested in trial NCT03935971?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03935971?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935971 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Contact Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
RECRUITING · Phase 2
-
Study of Apremilast in Atopic or Contact Dermatitis
COMPLETED · Phase 2
-
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.